Skip to content
608260826082RetRetRet808080

Drawing based on the description in the official product monograph. No photo yet.

“80 mg tablets are dark red-purple, film coated, round tablets debossed with "6082" on one side and "Ret 80" on the other”

6082 Ret 80 pill

Pill with imprint 6082 Ret 80 is purple & red, round and has been identified as Selpercatinib 80 mg. It is used for lung cancer and thyroid neoplasms. It is supplied by Eli Lilly Canada Inc.

Sold in Canada

Selpercatinib 80 mg

Brand
Retevmo
Imprint
6082 Ret 80
Strength
80 mg
Used for
Lung cancer and thyroid neoplasms
Color
Purple, Red
Shape
Round
Form
Tablet
Manufacturer
Eli Lilly Canada Inc
Drug class
Cancer medicine (kinase inhibitor)
Sold in
Canada
DIN
02565676

Source: Health Canada's Drug Product Database and the official product monograph. Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Selpercatinib pills and guides

What is Selpercatinib used for?

Selpercatinib is used for lung cancer and thyroid neoplasms.

Medicine type
Cancer medicine (kinase inhibitor)
Official uses from the US prescribing label

RET Fusion-Positive Non-Small Cell Lung Cancer

RETEVMO® is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test.

RET-Mutant Medullary Thyroid Cancer

RETEVMO is indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.

RET Fusion-Positive Thyroid Cancer

RETEVMO is indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).

Other RET Fusion-Positive Solid Tumors

RETEVMO is indicated for the treatment of adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.

From the FDA-approved label on DailyMed (published Sep 14, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • Your pill shows 6082 Ret 80. The parts can be split between the two sides, so turn the pill over and check both.
  • It is purple & red, round.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Sold in Canada as Retevmo by Eli Lilly Canada Inc.

In Canada: prescription only.

Ingredients

Active: Selpercatinib

Other pills with imprint 6082 Ret 80

Same imprint, different listing. Check the color, size and maker against your pill.

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Selpercatinib pills